Cargando…

Intrauterine contraception in nulliparous women: a prospective survey

BACKGROUND: Intrauterine contraception is a first-line option for young women, yet relatively few prospective studies have been performed in nulliparous women using currently available devices, and many providers are still reluctant to provide this option. METHODS: Between January 2012 and June 2014...

Descripción completa

Detalles Bibliográficos
Autores principales: Hall, Alexandra M, Kutler, Beth A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4717389/
https://www.ncbi.nlm.nih.gov/pubmed/25854550
http://dx.doi.org/10.1136/jfprhc-2014-101046
_version_ 1782410646975938560
author Hall, Alexandra M
Kutler, Beth A
author_facet Hall, Alexandra M
Kutler, Beth A
author_sort Hall, Alexandra M
collection PubMed
description BACKGROUND: Intrauterine contraception is a first-line option for young women, yet relatively few prospective studies have been performed in nulliparous women using currently available devices, and many providers are still reluctant to provide this option. METHODS: Between January 2012 and June 2014, 109 nulliparous women, aged 18–30 years, who had an intrauterine device (IUD) placed at a student health clinic [88 levonorgestrel-intrauterine system (LNG-IUS) users and 21 Cu T 380A (IUD) users] were surveyed at 1, 6, 12 and 18 months after insertion. RESULTS: Overall satisfaction was high; at follow-up survey 83% of 100 women (mean use 13.4 months) were ‘happy’ or ‘very happy’ with their IUD, and there were no differences in satisfaction between the two IUD types. Some 75% of participants stated that the insertion procedure went ‘very well’, despite 78% rating insertion pain as moderate to severe, and 46% experiencing vasovagal symptoms. The 12-month continuation rate was 89%, with discontinuations for expulsion (3%), side effects (6%), lack of anticipated benefit (1%) and pregnancy (1%). Users of the Cu T 380A were more likely to have heavy menses (74% vs 2%; p<0.0001) or moderate to severe cramping (68% vs 20%; p=0.0002) compared with LNG-IUS users. There were no uterine perforations or diagnoses of pelvic inflammatory disease. The rate of failed insertions during the study period was 6.2%. CONCLUSIONS: Despite significant symptoms with insertion, intrauterine contraception is safe, effective and ultimately well tolerated in nulliparous women and should be provided to this population in both university and community health settings.
format Online
Article
Text
id pubmed-4717389
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-47173892016-01-28 Intrauterine contraception in nulliparous women: a prospective survey Hall, Alexandra M Kutler, Beth A J Fam Plann Reprod Health Care Research BACKGROUND: Intrauterine contraception is a first-line option for young women, yet relatively few prospective studies have been performed in nulliparous women using currently available devices, and many providers are still reluctant to provide this option. METHODS: Between January 2012 and June 2014, 109 nulliparous women, aged 18–30 years, who had an intrauterine device (IUD) placed at a student health clinic [88 levonorgestrel-intrauterine system (LNG-IUS) users and 21 Cu T 380A (IUD) users] were surveyed at 1, 6, 12 and 18 months after insertion. RESULTS: Overall satisfaction was high; at follow-up survey 83% of 100 women (mean use 13.4 months) were ‘happy’ or ‘very happy’ with their IUD, and there were no differences in satisfaction between the two IUD types. Some 75% of participants stated that the insertion procedure went ‘very well’, despite 78% rating insertion pain as moderate to severe, and 46% experiencing vasovagal symptoms. The 12-month continuation rate was 89%, with discontinuations for expulsion (3%), side effects (6%), lack of anticipated benefit (1%) and pregnancy (1%). Users of the Cu T 380A were more likely to have heavy menses (74% vs 2%; p<0.0001) or moderate to severe cramping (68% vs 20%; p=0.0002) compared with LNG-IUS users. There were no uterine perforations or diagnoses of pelvic inflammatory disease. The rate of failed insertions during the study period was 6.2%. CONCLUSIONS: Despite significant symptoms with insertion, intrauterine contraception is safe, effective and ultimately well tolerated in nulliparous women and should be provided to this population in both university and community health settings. BMJ Publishing Group 2016-01 2015-04-08 /pmc/articles/PMC4717389/ /pubmed/25854550 http://dx.doi.org/10.1136/jfprhc-2014-101046 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
spellingShingle Research
Hall, Alexandra M
Kutler, Beth A
Intrauterine contraception in nulliparous women: a prospective survey
title Intrauterine contraception in nulliparous women: a prospective survey
title_full Intrauterine contraception in nulliparous women: a prospective survey
title_fullStr Intrauterine contraception in nulliparous women: a prospective survey
title_full_unstemmed Intrauterine contraception in nulliparous women: a prospective survey
title_short Intrauterine contraception in nulliparous women: a prospective survey
title_sort intrauterine contraception in nulliparous women: a prospective survey
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4717389/
https://www.ncbi.nlm.nih.gov/pubmed/25854550
http://dx.doi.org/10.1136/jfprhc-2014-101046
work_keys_str_mv AT hallalexandram intrauterinecontraceptioninnulliparouswomenaprospectivesurvey
AT kutlerbetha intrauterinecontraceptioninnulliparouswomenaprospectivesurvey